Amylyx Pharmaceuticals, Inc. (AMLX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.7800 |
| Open | 1.7900 |
| Bid | 1.7200 x 1000 |
| Ask | 1.7700 x 1200 |
| Day's range | 1.7000 - 1.8400 |
| 52-week range | 1.7000 - 30.5000 |
| Volume | |
| Avg. volume | 3,336,511 |
| Market cap | 119.69M |
| Beta (5Y monthly) | -0.93 |
| PE ratio (TTM) | 2.51 |
| EPS (TTM) | 0.7000 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.25 |
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksBiotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Business WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CAMBRIDGE, Mass., April 10, 2024--Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial
© 2024 Yahoo. All rights reserved.